Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Breast Neoplasms 11Triple Negative Breast Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Multiple Myeloma 2Meningeal Neoplasms 2Lymphoma, Non-Hodgkin 2HER2-positive Breast Cancer 2Stomach Neoplasms 1Rectal Neoplasms 1Pathologic Complete Response 1Meningeal Carcinomatosis 1Hemangiosarcoma 1Colorectal Neoplasms 1Brain Neoplasms 1Adenocarcinoma 1

Interventions

tucatinib 2Trastuzumab 2Spinal Puncture 2Nivolumab 2Capecitabine 2Specimen Handling 1Radiotherapy 1Phlebotomy 1Methotrexate 1Magnetic Resonance Spectroscopy 1Blood Specimen Collection 1AZD1390 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Meningeal Neoplasms × tucatinib × Clear all
NCT06016387 2026-02-23

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

Sunnybrook Health Sciences Centre

Phase 2 Recruiting
30 enrolled
Breast

Breast Neoplasms, Meningeal Neoplasms

NCT05800275 2025-11-18

ETIC-LM

UNICANCER

Phase 2 Recruiting
30 enrolled
CNS

Meningeal Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡